# Humacyte's Bioengineered Blood Vessel Outperforms the Standard of Care for Women on Dialysis in Phase 3 Results Presented at the Society for Vascular Surgery Vascular Annual Meeting
Canonical URL: https://biopharmsignal.com/news/HUMA/humacyte-s-bioengineered-blood-vessel-outperforms-the-standard-of-care-for-women-on-dialysis-in-phase-3-results-presented-at-the-society-for-vascular-surgery-vascular-annual-meeting
Ticker: HUMA
Company: Humacyte
Source: Humacyte
Published: 2026-06-25 13:46 EST
Original Source URL: https://investors.humacyte.com
## Summary

– Positive results from the V012 Phase 3 study were presented at the Society for Vascular Surgery's Vascular Annual Meeting in Boston – – Women who received Humacyte's ATEV experienced an average of three more months without a dialysis catheter than women who received AV fistula, the current

## Article Body
– Positive results from the V012 Phase 3 study were presented at the Society for Vascular Surgery's Vascular Annual Meeting in Boston – – Women who received Humacyte's ATEV experienced an average of three more months without a dialysis catheter than women who received AV fistula, the current
## Recent Company News
- 2026-06-25 13:46 EST — [Humacyte's Bioengineered Blood Vessel Outperforms the Standard of Care for Women on Dialysis in Phase 3 Results Presented at the Society for Vascular Surgery Vascular Annual Meeting](https://biopharmsignal.com/news/HUMA/humacyte-s-bioengineered-blood-vessel-outperforms-the-standard-of-care-for-women-on-dialysis-in-phase-3-results-presented-at-the-society-for-vascular-surgery-vascular-annual-meeting) — Source: Humacyte
- 2026-06-25 13:46 EST — [Humacyte, Inc. Announces Pricing of Public Offering of Common Stock](https://biopharmsignal.com/news/HUMA/humacyte-inc-announces-pricing-of-public-offering-of-common-stock) — Source: Humacyte
- 2026-06-25 13:46 EST — [Humacyte ATEV Met Superiority Primary Endpoint Compared to Standard of Care AV Fistula in Interim Analysis of V012 Phase 3 Study in Female Dialysis Access Patients](https://biopharmsignal.com/news/HUMA/humacyte-atev-met-superiority-primary-endpoint-compared-to-standard-of-care-av-fistula-in-interim-analysis-of-v012-phase-3-study-in-female-dialysis-access-patients) — Source: Humacyte
- 2026-06-25 13:46 EST — [Humacyte, Inc. Announces Proposed Public Offering of Common Stock](https://biopharmsignal.com/news/HUMA/humacyte-inc-announces-proposed-public-offering-of-common-stock) — Source: Humacyte
- 2026-06-25 13:46 EST — [Humacyte Announces Presentation at VASA Meeting of Research Highlighting Self-Repair of ATEV After Cannulation for Dialysis Access](https://biopharmsignal.com/news/HUMA/humacyte-announces-presentation-at-vasa-meeting-of-research-highlighting-self-repair-of-atev-after-cannulation-for-dialysis-access) — Source: Humacyte
## Related News
- 2026-07-21 12:00 EST — MOR — [Novartis delivered sales growth in Q2 and further advanced the pipeline; Full-year guidance reaffirmed](https://biopharmsignal.com/news/MOR/novartis-delivered-sales-growth-in-q2-and-further-advanced-the-pipeline-full-yea-63a32b47)
- 2026-07-20 20:05 EST — RANI — [Rani Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/RANI/rani-therapeutics-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-ec56b3b0)
- 2026-07-20 14:53 EST — IPHA — [Innate Pharma announces Completion of Enrollment in Phase 1 Dose Escalation Study of IPH4502, a Novel Nectin-4 Exatecan Antibody-Drug Conjugate (ADC)](https://biopharmsignal.com/news/IPHA/innate-pharma-announces-completion-of-enrollment-in-phase-1-dose-escalation-stud-0778493f)
- 2026-07-20 13:05 EST — ACAD — [Acadia Pharmaceuticals Receives FDA Fast Track Designation for Remlifanserin in Alzheimer's Disease Psychosis](https://biopharmsignal.com/news/ACAD/acadia-pharmaceuticals-receives-fda-fast-track-designation-for-remlifanserin-in--f36b622c)
- 2026-07-20 13:00 EST — ENLV — [Enlivex Treasury Portfolio Update: NAV Per Ordinary Share $66.16; Total Treasury Holdings Valued at Approximately $1.1 Billion](https://biopharmsignal.com/news/ENLV/enlivex-treasury-portfolio-update-nav-per-ordinary-share-66-16-total-treasury-ho-9d036ef9)